Halozyme Therapeutics Inc (HALO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $11.43B
Last updated: Nov 17, 2026 at 11:06 AM ET
Halozyme Therapeutics Inc (HALO) Earnings: Report Dates and Results
Halozyme Therapeutics (HALO) is expected to report earnings on Jan 26, 2027. In the quarter ended Sep 30, 2026, Halozyme Therapeutics reported EPS of $2.27, above the $2.17 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
HALO has an expected report date of Jan 26, 2027.
HALO Earnings Call
The latest HALO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, HALO beat 28, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $492.97M, up 39.2% from $354.26M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.27 | $2.17 | N/A | +4.61% | Beat | +32.0% | 6 | 1 up, 0 down | Nov 5, 2026 | $492.97M |
| Jun 30, 2026 | $2.17 | $1.73 | $1.72 - $1.90 | +25.43% | Beat | +40.9% | 6 | 1 up, 0 down | Aug 6, 2026 | $481.00M |
| Mar 31, 2026 | $1.22 | $1.76 | N/A | -30.61% | Miss | +10.0% | 5 | 2 up, 1 down | May 11, 2026 | $376.71M |
| Dec 31, 2025 | -$0.24 | $2.20 | $2.14 - $2.23 | -110.91% | Miss | -119.0% | 5 | 5 up, 0 down | Feb 17, 2026 | $451.77M |
| Sep 30, 2025 | $1.72 | $1.63 | $1.47 - $1.69 | +5.52% | Beat | +35.4% | 7 | N/A | Nov 3, 2025 | $354.26M |
| Jun 30, 2025 | $1.54 | $1.27 | $1.00 - $1.41 | +21.26% | Beat | +69.2% | 7 | 1 up, 0 down | Aug 5, 2025 | $325.72M |
| Mar 31, 2025 | $1.11 | $0.95 | $0.88 - $0.99 | +16.84% | Beat | +40.5% | 6 | 0 up, 1 down | May 6, 2025 | $264.86M |
| Dec 31, 2024 | $1.26 | $1.16 | $1.11 - $1.23 | +8.73% | Beat | +53.7% | 6 | 0 up, 2 down | Feb 18, 2025 | $298.01M |
| Sep 30, 2024 | $1.27 | $0.98 | $0.93 - $1.05 | +29.59% | Beat | +69.3% | 8 | 0 up, 0 down | Oct 31, 2024 | $290.08M |
| Jun 30, 2024 | $0.91 | $0.76 | $0.73 - $0.87 | +19.74% | Beat | +23.0% | 7 | 1 up, 0 down | Aug 6, 2024 | $231.35M |
| Mar 31, 2024 | $0.79 | $0.70 | $0.63 - $0.83 | +12.86% | Beat | +68.1% | 6 | 0 up, 0 down | May 7, 2024 | $195.88M |
| Dec 31, 2023 | $0.82 | $0.83 | $0.79 - $0.85 | -1.20% | Miss | +70.8% | 6 | 2 up, 0 down | Feb 20, 2024 | $230.04M |
| Sep 30, 2023 | $0.75 | $0.71 | $0.66 - $0.78 | +5.63% | Beat | +1.4% | 6 | 0 up, 2 down | Nov 6, 2023 | $216.03M |
| Jun 30, 2023 | $0.74 | $0.64 | $0.57 - $0.66 | +15.63% | Beat | +39.6% | 6 | 1 up, 0 down | Aug 8, 2023 | $221.04M |
| Mar 31, 2023 | $0.47 | $0.48 | $0.39 - $0.56 | -2.08% | Miss | 0.0% | 6 | 0 up, 1 down | May 9, 2023 | $162.14M |
| Dec 31, 2022 | $0.48 | $0.47 | $0.42 - $0.53 | +2.13% | Beat | +14.3% | 6 | 0 up, 0 down | Feb 21, 2023 | $181.50M |
| Sep 30, 2022 | $0.74 | $0.51 | $0.42 - $0.58 | +45.10% | Beat | +34.5% | 5 | 2 up, 0 down | Nov 8, 2022 | $208.98M |
| Jun 30, 2022 | $0.53 | $0.50 | $0.43 - $0.57 | +6.00% | Beat | -19.7% | 6 | 0 up, 0 down | Aug 9, 2022 | $152.37M |
| Mar 31, 2022 | $0.47 | $0.49 | $0.44 - $0.53 | -4.08% | Miss | +27.0% | 6 | 2 up, 0 down | May 10, 2022 | $117.28M |
| Dec 31, 2021 | $0.42 | $0.41 | $0.37 - $0.43 | +2.44% | Beat | -16.0% | 8 | 3 up, 0 down | Feb 22, 2022 | $102.00M |
| Sep 30, 2021 | $0.55 | $0.48 | N/A | +14.58% | Beat | +120.0% | N/A | N/A | Nov 2, 2021 | $115.83M |
| Jun 30, 2021 | $0.66 | $0.44 | $0.32 - $0.60 | +50.00% | Beat | +247.4% | 9 | N/A | Aug 9, 2021 | $136.46M |
| Mar 31, 2021 | $0.37 | $0.31 | $0.26 - $0.37 | +19.35% | Beat | N/A | 9 | N/A | May 10, 2021 | $89.02M |
| Dec 31, 2020 | $0.50 | $0.53 | $0.45 - $0.59 | -5.66% | Miss | N/A | 10 | N/A | Feb 23, 2021 | $121.70M |
| Sep 30, 2020 | $0.25 | $0.21 | $0.12 - $0.23 | +19.05% | Beat | N/A | 10 | N/A | Nov 2, 2020 | $65.32M |
| Jun 30, 2020 | $0.19 | $0.25 | $0.09 - $0.42 | -24.00% | Miss | N/A | 11 | N/A | Aug 10, 2020 | $55.22M |
| Mar 31, 2020 | -$0.04 | -$0.04 | -$0.14 - $0.16 | 0.00% | In line | -500.0% | 11 | N/A | May 11, 2020 | $25.35M |
| Dec 31, 2019 | -$0.24 | -$0.14 | -$0.25 - $0.11 | -71.43% | Miss | N/A | 10 | N/A | Feb 24, 2020 | $53.66M |
| Sep 30, 2019 | -$0.17 | -$0.13 | -$0.18 - -$0.05 | -30.77% | Miss | N/A | 10 | N/A | Nov 12, 2019 | $46.23M |
| Jun 30, 2019 | -$0.10 | -$0.15 | -$0.22 - -$0.03 | +33.33% | Beat | N/A | 10 | N/A | Aug 6, 2019 | $39.15M |
| Mar 31, 2019 | $0.01 | $0.05 | -$0.11 - $0.11 | -80.00% | Miss | N/A | 10 | N/A | May 7, 2019 | $56.95M |
| Dec 31, 2018 | -$0.01 | -$0.03 | -$0.07 - $0.04 | +66.67% | Beat | -101.2% | 11 | N/A | Feb 21, 2019 | $60.23M |
| Sep 30, 2018 | -$0.19 | -$0.23 | -$0.25 - -$0.20 | +17.39% | Beat | -1050.0% | 10 | N/A | Nov 6, 2018 | $25.56M |
| Jun 30, 2018 | -$0.16 | -$0.22 | -$0.25 - -$0.18 | +27.27% | Beat | N/A | 9 | N/A | Aug 7, 2018 | $35.20M |
| Mar 31, 2018 | -$0.19 | -$0.22 | -$0.28 - -$0.13 | +13.64% | Beat | N/A | 11 | N/A | May 10, 2018 | $30.87M |
| Dec 31, 2017 | $0.85 | $0.77 | $0.53 - $0.88 | +10.39% | Beat | N/A | 11 | N/A | Feb 20, 2018 | $189.56M |
| Sep 30, 2017 | $0.02 | -$0.11 | -$0.29 - $0.25 | +118.18% | Beat | N/A | 9 | N/A | Nov 7, 2017 | $63.73M |
| Jun 30, 2017 | -$0.23 | -$0.24 | -$0.26 - -$0.22 | +4.17% | Beat | N/A | 10 | N/A | Aug 8, 2017 | $33.75M |
| Mar 31, 2017 | -$0.26 | -$0.24 | N/A | -8.33% | Miss | N/A | N/A | N/A | May 9, 2017 | $29.57M |
| Dec 31, 2016 | -$0.21 | -$0.28 | N/A | +25.00% | Beat | -800.0% | N/A | N/A | Feb 28, 2017 | $39.00M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $4.13, down 2.4% from the year before. It was -$0.81 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $4.13 | -2.4% |
| Dec 31, 2024 | $4.23 | +52.2% |
| Dec 31, 2023 | $2.78 | +25.2% |
| Dec 31, 2022 | $2.22 | +11.0% |
| Dec 31, 2021 | $2.00 | +122.2% |
| Dec 31, 2020 | $0.90 | N/A |
| Dec 31, 2019 | -$0.50 | N/A |
| Dec 31, 2018 | -$0.55 | -244.7% |
| Dec 31, 2017 | $0.38 | N/A |
| Dec 31, 2016 | -$0.81 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,400 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,370 | 12 | |
| 2026Q2 | Jun 30, 2026 | 5,712 | 10 | |
| 2026Q1 | Mar 31, 2026 | 6,899 | 13 | |
| 2025Q4 | Dec 31, 2025 | 5,757 | 11 | |
| 2025Q3 | Sep 30, 2025 | 5,877 | 9 | |
| 2025Q2 | Jun 30, 2025 | 7,793 | 12 | |
| 2025Q1 | Mar 31, 2025 | 6,568 | 11 | |
| 2024Q4 | Dec 31, 2024 | 7,210 | 11 |
2026Q3 Earnings Call
Opening remarks
Tram Bui Vice President of Investor Relations Thank you, operator. Good afternoon, and welcome to Halozyme's Third Quarter 2026 Financial and Operating Results Conference Call. In addition to the press release issued today after the market close, you can find a supplementary slide presentation that will be referenced during today's call in the Investor Relations section of our website. Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Darren Snellgrove, our Chief Financial Officer, who will review our financial results and outlook. On today's call, we will be making forward-looking statements as outlined on Slide 2. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation. I will now turn the call over to Dr. Helen Torley, and we will start on Slide 3.
Helen Torley President and Chief Executive Officer Thank you, Tram, and good afternoon, everyone. I'm pleased to report another exceptionally strong quarter for Halozyme as more patients, physicians and health care systems experience the benefits of subcutaneous delivery with ENHANZE. This is reflected in the record total and royalty revenues. And operationally, we continue to demonstrate new growth opportunities resulting from our compounding platform engine, ENHANZE. In and post the quarter, we significantly expanded the ENHANZE opportunity with 3 current partners expanding their agreements to add 4 new target nominations. Additionally, 3 ENHANZE-enabled programs, 1 each from Pfizer, Incyte and argenx, advanced into Phase I development. And GSK plans to initiate a Phase Ib study of a subcutaneous formulation of belantamab with ENHANZE. With this planned start, we are on track to achieve 13 ENHANZE programs in clinical development by year-end. Importantly, we also advanced our 2 hyperconcentration technologies, Hypercon and Aerocon, the new name for Surf Bio, moving these closer to clinical testing. All of this contributed to the record total revenue, royalty revenue and adjusted EBITDA for Q3. Total revenue increased 39% year-over-year to $493 million, driven by royalty revenue, which increased 44% to a record $341 million. These results reflect the continued growth of our established commercial partner product portfolio and the growing contributions from the newer launches, which is resulting in a diversified and growing set of royalty revenue streams. Profitability remained strong during the quarter with adjusted EBITDA of $336 million and an adjusted EBITDA margin of 68%, reflecting our disciplined execution. Based on this strength, we are raising our full year 2026 financial guidance. Darren will be discussing this in greater detail. Turning to Slide 4.
Frequently Asked Questions About HALO
When is Halozyme Therapeutics's next earnings date?
Halozyme Therapeutics's next earnings report is expected for Jan 26, 2027.
Did HALO beat earnings estimates last quarter?
Yes. Halozyme Therapeutics reported EPS of $2.27 for the quarter ended Sep 30, 2026, above the $2.17 estimate, a 4.61% surprise.
What EPS do analysts expect from HALO next quarter?
The consensus EPS estimate for Halozyme Therapeutics for the quarter ending Dec 31, 2026 is $2.70 from 11 analysts, with estimates from $2.53 to $2.92.
How often does HALO beat earnings estimates?
Halozyme Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of -7.39%.
HALO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors